Pharmaceutical Technology on MSN3d
Lundbeck’s amlenetug gains orphan drug status in Japan for MSA
Lundbeck has gained orphan drug designation (ODD) from Japan’s Ministry of Health, Labor and Welfare (MHLW) for amlenetug to ...
Pharmabiz4d
Lundbeck’ amlenetug receives Japanese orphan drug designation for treatment of multiple system atrophy
H. Lundbeck A/S (Lundbeck), a global pharmaceutical company, announced that the Ministry of Health, Labor, and Welfare (MHLW) in Japan has granted Orphan Drug Designation (ODD) to its investigational ...
abc271mon
Lundbeck's potential treatment amlenetug for Multiple System Atrophy receives Fast Track Designation from the FDA
The FDA has granted Fast Track Designation to Lundbeck's investigational drug, amlenetug, a potential new treatment option targeting Multiple System Atrophy (MSA). Lundbeck has recently initiated ...
PharmaTimes1mon
Amlenetug receives FDA Fast Track Designation
Lundbeck’s investigational drug, amlenetug, has been granted Fast Track Designation by the US Food and Drug Administration (FDA) as a potential treatment for multiple system atrophy (MSA). This ...
Taiwan News5d
Lundbeck's potential treatment for Multiple System Atrophy granted Orphan Drug Designation in Japan
VALBY, Denmark, March 10, 2025 /PRNewswire/ -- The Ministry of Health, Labor, and Welfare (MHLW) in Japan has granted Orphan Drug Designation (ODD) to Lundbeck's investigational drug, amlenetug, a ...
Yahoo Finance1mon
Lundbeck gains FDA fast track designation for MSA therapy amlenetug
Lundbeck has received the US Food and Drug Administration’s (FDA) fast track designation for its investigational drug amlenetug, a potential treatment for multiple system atrophy (MSA).
PharmiWeb1mon
Lundbeck’s potential treatment amlenetug for Multiple System Atrophy receives Fast Track Designation from the FDA
The FDA has granted Fast Track Designation to Lundbeck’s investigational drug, amlenetug, a potential new treatment option targeting Multiple System Atrophy (MSA). Lundbeck has recently initiated ...
Yahoo Finance1mon
Lundbeck's potential treatment amlenetug for Multiple System Atrophy receives Fast Track Designation from the FDA
The FDA has granted Fast Track Designation to Lundbeck's investigational drug, amlenetug, a potential new treatment option targeting Multiple System Atrophy (MSA). Lundbeck has recently initiated ...